Sorafenib: Rays of hope in thyroid cancer

Thyroid

Volumn 20, Issue 12, 2010, Pages 1351-1358

  Duntas, Leonidas H ^a   Bernardini, Renato ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; B RAF KINASE; B RAF KINASE INHIBITOR; DEXAMETHASONE; DOXORUBICIN; IRINOTECAN; NELFINAVIR; PHENYTOIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RADIOACTIVE IODINE; RAPAMYCIN; RIFABUTIN; SORAFENIB; SUNITINIB; TIPIFARNIB;

ADVANCED CANCER; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLEPHARITIS; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DESQUAMATION; DIARRHEA; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSFUNCTIONAL TEAR SYNDROME; DYSPNEA; FATIGUE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY DISEASE; LACRIMAL GLAND FUNCTION; LIVER CELL CARCINOMA; LUNG HEMORRHAGE; MENTAL DISEASE; MUSCULOARTICULAR PAIN; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT RESPONSE; TUBEROUS SCLEROSIS; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, PAPILLARY; DISEASE-FREE SURVIVAL; DRUG INTERACTIONS; HUMANS; PROTEIN-TYROSINE KINASES; PYRIDINES; THYROID NEOPLASMS;

EID: 78649703084     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2010.0056     Document Type: Review

References (75)

1. Krause DS, Van Etten RA 2005 Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172-187.
2. Tabernero J 2007 The role of VEGF and EGFR inhibitor: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5:203-220.
3. Fassnacht M, Kreissl MC, Weismann D, Alolio B 2009 New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther 123:117-141.
4. Staehler M, Haseke N, Zilinberg E, Stadler T, Karl A, Siebels M, Duerr HR, Siegert S, Jauch KW, Bruns CJ, Stief CG 2010 Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. Urol Oncol 28:139-144.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group 2008 Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390.
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z 2009 Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34.
7. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A, Santoro M 2005 The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mi-togenic phenotype of thyroid cancer cells. J Clin Invest 115:1068-1081.
8. Kumar CC 1998 Signaling by integrin receptors. Oncogene 17:1365-1373.
9. Roberts PJ, Der CJ 2007 Targeting the RAF-MEK-ERK mi-togen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291-3310.
10. Ferrara N, Gerber HP, LeCouter J 2003 The biology of VEGF and its receptors. Nat Med 9:669-676.
11. Ferrara N 2004 Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581-611. (Pubitemid 39099316)
12. Mori T, Sasaki J, Aoyama Y, Sera T 2010 Hypoxia-specific downregulation of endogenous human VEGF-A gene by hypoxia-driven expression of artificial transcription factor. Mol Biotechnol 46:134-139.
13. Carroll VA, Ashcroft M 2006 Role of hypoxia-inducible factor (HIF)-1 alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 66:6264-6270.
14. Braga-Basaria M, Ringel MD 2003 Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. J Clin Endocrinol Metab 88:1947-1960.
15. Vadysirisack DD, Venkateswaran A, Zhang Z, Jhiang SM 2007 MEK signaling modulates sodium iodide symporter at multiple levels and in a paradoxical manner. Endocr Relat Cancer 14:421-432.
16. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Z, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gus-terson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yen ST, Weber BL, Seigler HF, Darrow TL, Pa-terson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA 2002 Mutations of the BRAF gene in human cancer. Nature 417:949-954.
17. Riesco-Eizaquirre G, Gutierrez-Martinez F, Garcia-Cabezas MA, Nistal M, Santisteban P 2006 The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to impairment of Na\+/I-targeting to the membrane. Endocr Relat Cancer 13:257-269.
18. Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, Basolo F, Miccoli P, Pacini F, Pinchera A, Elisei R 2008 BRAF V600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer 15:511-520.
19. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F 2008 BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin En-docrinol Metab 93:3943-3949.
20. Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA 2006 Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 12:1785-1793.
21. Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozo-poulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D, Mitsiades N 2007 Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Mol Cancer Ther 6:1070-1080.
22. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK, Xing M 2008 Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylino-sitol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93:3106-3116.
23. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA 2009 Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3-CA, and AKT1. Cancer Res 69:4885-4893.
24. Lackey K, Cory M, Davis R, Frye SV, Harris PA, Hunter RN, Jung DK, McDonald OB, McNutt RW, Peel MR, Rutkowske RD, Veal JM, Wood ER 2000 The discovery of potent cRAF1 kinase inhibitors. Bioorg Med Chem Lett 10:223-226.
25. Bankston D, Dumas J, Natero R, Riedl B, Monahan MK, Sibley R 2002 A scalable synthesis of BAY 43-9600: a potent Raf kinase inhibitor for the treatment of cancer. Org Proc Res Dev 6:777-781.
26. Strumberg D 2005 Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 41:773-784.
27. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI 2006 Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24.
28. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter CA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Hergard S, Insko DE, Insko MA, Lai AG, Leilas JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ 2005 A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329-336.
29. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ 2005 Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11:5472-5480.
30. Escudier B, Eisen T, Stadler WM, Szccylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hoflilena G, Shan M, Pena C, Lathia C, Bukowski RM 2009 Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312-3318.
31. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B 2007 Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12:426-437.
32. Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, Strumberg D, Brendel E, Haase CG, Schwartz B, Piccart M 2005 Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92: 1855-1861.
33. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S 2005 Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-972.
34. Keating GM, Santoro A 2009 Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 69:223-240.
35. Mross K, Steinbild S, Baas F, Gmehling D, Radtke M, Vo-liotis D, Brendel E, Christensen O, Unger C 2007 Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 43:55-63.
36. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM 2009 Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cancer cell carcinoma. J Clin Oncol 10:1280-1289.
37. Welker MW, Lubomierski N, Gog C, Hermann E, Engels K, Vogl TJ, Bechstein WO, Zeuzem S, Trojan J 2010 Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions. J Chemother 3:205-211.
38. Roberts C, Mateus C, Spatz A, Wechsler J, Escudier B 2009 Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 60:299-305.
39. Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK 2009 Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 161:1045-1051.
40. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Mon-tella L, Rizzo S, Venditti O, Frezza AM, Caraglia M, Colucci G, Del Prete S, Tonini G 2010 Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 15:85-92.
41. Jantzem H, Dupre-Goetghebeur D, Spindler P, Merrer J 2009 Sorafenib-induced multiple eruptive keratoacanthomas. Ann Dermatol Venereol 136:894-897.
42. Smith KJ, Haley H, Hamza S, Skelton HG 2009 Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg 35:1766-1770.
43. Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP 2009 Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20:807-815.
44. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ 2008 Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 13:1084-1096.
45. Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, Hwang J, Vilalona-Calero MA, Dees EC, Lewis LD, Fakih MG, Edelman MJ, Millard F, Frank RC, Hohl RJ, Ratain MJ 2009 Phase I and pharmacokinetics study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 27:1800-1805.
46. Basti S 2007 Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nurs 30:S10-S16.
47. Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M, Nakagawa K 2009 Sorafenib inhibits non-small cell lung cancer growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. Cancer Res 69:6515-6521.
48. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109.
49. Bran B, Bran G, Hoermann K, Riedel F 2009 The platelet derived growth factor receptor as a target for vascular en-dothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer. Int J Oncol 34:255-261.
50. Preto A, Gonçalves J, Rebocho AP, Figueiredo J, Meireles AM, Rocha AS, Vasconcelos HM, Seca H, Seruca R, Soares P, Sobrinho-Simões M 2009 Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer 9:387.
51. Keefe SM, Cohen MA, Brose MS 2010 Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications. Clin Cancer Res 16:778-783.
52. Kim S, Yazici YD, Calzada G, Wang ZY, Younes MN, Jasser SA, El-Naggar AK, Myers JN 2007 Sorafenib inhibits the angiogenesis and growth of orthotropic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 6: 1785-1792.
53. Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G 2009 Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 6:219-228.
54. Illouz F, Laboureau-Soares S, Dubois S, Rohmer V, Rodien P 2009 Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol 160:331-336.
55. Morshed SA, Latif R, Davies TF 2009 Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology 150:519-529.
56. Rivas M, Santisteban P 2003 TSH-activated signaling pathways in thyroid tumorigenesis. Mol Cell Endocrinol 213: 31-45.
57. Rogiers A, Wolter P, Op de Beeck K, Thijs M, Decallonne B, Schöffski P 2010 Shrinkage of thyroid volume in sunitinibtreated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? Thyroid 20:317-322.
58. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L 2007 A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92:3531-3534.
59. Hershman JM, Liwanpo L 2010 How does sunitinib cause hypothyroidism? Thyroid 20:243-244.
60. Abdulrahman RM, Verloop H, Hoftijzer H, Verburg E, Hovens GC, Corssmit EP, Reiners C, Gelderblom H, Pereira AM, Kapiteijn E, Romijn JA, Visser TJ, Smit JW 2010 Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab 95: 3758-3762.
61. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719.
62. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr., Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684.
63. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corss-mit EP, Gelderblom H, Wejers K, Pereira AM, Huijberts M, Kapiteijn E, Romijn JA, Smit JW 2009 Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 161:923-931.
64. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL 2010 Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M.D. Anderson experience. J Clin Endocrinol Metab 95:2588-2595.
65. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr., Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Vilalona-Calero MA, Shah MH 2010 Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28:2323-2330.
66. Fagin JA, Tuttle M, Pfister D 2010 Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer. J Clin En-docrinol Metab 95:2621-2624.
67. Tortora G, Ciardiello F, Gasparini G 2008 Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol 5:521-530.
68. Takimoto CH, Awada A 2008 Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 61:535-548.
69. Brüning A, Burger P, Vogel M, Gingelmaier A, Friese K, Burges A 2010 Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib. Invest New Drugs 28:535-542.
70. Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, Wright JJ, Kurzrock R 2009 Phase I trial of a combination of the mul-tikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res 15:7061-7068.
71. Sherman SI 2009 Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab 23:713-722.
72. Sugawara M, Geffner DL, Martinez D, Hershman JM 2009 Novel treatment of medullary thyroid cancer. Curr Opin Endocrinol Diabetes Obes 16:367-372.
73. Lee N, Woodrum CL, Nobil AM, Rauktys AE, Messina MP, Dabora SL 2009 Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapa-mycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol 9:8.
74. Papewalis C, Wuttke M, Schinner S, Willenberg HS, Baran AM, Scherbaum WA, Schott M 2009 Role of the novel m TOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer. Horm Metab Res 41:752-756.
75. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Thng CH, Chow P, Ong HS, Chung A, Soo KC 2009 Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med 13:2673-2683.